Jin Yang Pharmaceutical Co., Ltd.

Research Jin Yang Pharmaceutical Co., Ltd. (007370.KQ) on Bullrun: market cap KRW 54.84B, dividend yield 3.9%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 54.84B; dividend yield is 3.9%.

Peer valuation comparison

Latest dividend yield is 3.87% versus a Healthcare sector median of 2.4% (61.3% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 54.84Bn/a3.9%150

Dividend history

Latest trailing dividend snapshot: annual dividend/share 150 KRW, yield 3.9%.

About Jin Yang Pharmaceutical Co., Ltd.

Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports its products. Jin Yang Pharmaceutical Co., Ltd. was founded in 1971 and is headquartered in Seoul, South Korea.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Jin Yang Pharmaceutical Co., Ltd.'s market cap?

Jin Yang Pharmaceutical Co., Ltd.'s market capitalization is KRW 54.84B.

Does Jin Yang Pharmaceutical Co., Ltd. pay a dividend?

Jin Yang Pharmaceutical Co., Ltd. has a dividend yield of 3.9%.

What does Jin Yang Pharmaceutical Co., Ltd. do?

Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports its products. Jin Yang Pharmaceutical Co., Ltd. was founded in 1971 and is headquartered in Seoul, South Korea.